XHELOPTOMED
Market cap85mUSD
Dec 20, Last price
4.17EUR
1D
-1.88%
1Q
-21.17%
IPO
-32.74%
Name
Optomed Oyj
Chart & Performance
P/E
—
P/S
5.43
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.84%
Rev. gr., 5y
0.87%
Revenues
15m
+3.00%
Net income
-4m
L-18.84%
CFO
-615k
L-74.05%
Earnings
Feb 13, 2025
Profile
Optomed Oyj, a medical technology company, manufactures and sells handheld fundus cameras and screening software in Finland, China, and internationally. The company operates through two segments, Devices and Software segments. The company develops, manufactures, and sells fundus camera products, which are used by ophthalmologists, pediatricians, endocrinologists, neurologists, and primary care professionals. It offers camera products under the Optomed Smartscope Pro, Optomed Aurora, Optomed Polaris, and Optomed Halo brands, as well as OEM cameras, including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal brand names. The company also provides Avenue Eye Screen, a workflow management software for screening and monitoring of eye diseases, such as diabetic retinopathy; Avenue Archive, an application software for displaying, archiving, and transmitting healthcare information; Avenue Telemedicine, a telemedicine solution for remote image analysis; Avenue AI, an automated diabetic retinopathy screening service; and Avenue Sync, a software solution for integrating fundus camera to the hospital image archive and worklist server. In addition, it offers Avenue Cancer Screen, a screening process management software for breast, cervical, and colorectal cancer; Optomed RIS, a software solution for healthcare imaging units for enhancing the diagnostic process and treatment decisions; Sectra PACS, a modular system optimized for use by high production healthcare providers; Optomed Service Portal, a support function for healthcare units that order and produce imaging services; Facad, a tracing software for visible light imaging and cephalometric measurements; and Sectra PACS Pathology, a digital pathology solution, which allows scanned glass slides to be distributed and diagnosed. Further, the company provides professional IT consulting services for government institutions. It sells its products and solutions through OEMs, distributors, and direct sales. The company's customers include hospitals, eye clinics, and optician chains and stores. The company was incorporated in 2004 and is headquartered in Oulu, Finland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 15,100 3.00% | 14,660 -1.28% | 14,850 14.13% | ||||||
Cost of revenue | 10,947 | 7,358 | 7,054 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 4,153 | 7,302 | 7,796 | ||||||
NOPBT Margin | 27.50% | 49.81% | 52.50% | ||||||
Operating Taxes | (78) | (79) | (78) | ||||||
Tax Rate | |||||||||
NOPAT | 4,231 | 7,381 | 7,874 | ||||||
Net income | (4,441) -18.84% | (5,472) 28.78% | (4,249) 33.74% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,992 | 9,012 | 1,012 | ||||||
BB yield | -6.49% | -16.44% | -0.77% | ||||||
| Debt | |||||||||
Debt current | 1,503 | 1,399 | 1,660 | ||||||
Long-term debt | 4,862 | 6,814 | 7,785 | ||||||
Deferred revenue | 4,286 | 5,753 | |||||||
Other long-term liabilities | 1,000 | (4,286) | (5,753) | ||||||
Net debt | (753) | (8,944) | (5,633) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (615) | (2,370) | (2,940) | ||||||
CAPEX | (213) | (3,029) | (2,574) | ||||||
Cash from investing activities | (2,412) | (3,029) | (2,574) | ||||||
Cash from financing activities | 1,609 | 7,003 | 1,637 | ||||||
FCF | 10,195 | 2,729 | 7,882 | ||||||
| Balance | |||||||||
Cash | 7,118 | 8,524 | 6,804 | ||||||
Long term investments | 8,633 | 8,274 | |||||||
Excess cash | 6,363 | 16,424 | 14,336 | ||||||
Stockholders' equity | 19,857 | 19,838 | 16,548 | ||||||
Invested Capital | 18,857 | 10,661 | 10,948 | ||||||
ROIC | 28.67% | 68.32% | 27.80% | ||||||
ROCE | 16.27% | 26.58% | 30.28% | ||||||
| EV | |||||||||
Common stock shares outstanding | 16,707 | 14,641 | 13,441 | ||||||
Price | 3.68 -1.74% | 3.75 -61.79% | 9.80 35.73% | ||||||
Market cap | 61,480 12.13% | 54,829 -58.38% | 131,726 37.56% | ||||||
EV | 60,727 | 45,885 | 126,093 | ||||||
EBITDA | 6,346 | 10,447 | 10,485 | ||||||
EV/EBITDA | 9.57 | 4.39 | 12.03 | ||||||
Interest | 288 | 115 | 101 | ||||||
Interest/NOPBT | 6.93% | 1.57% | 1.30% | ||||||